10-Q: Eledon Q3 2025: Mixed Trial Results, Capital Raises

Eledon Pharmaceuticals reports a significant net loss in Q3 2025, alongside mixed Phase 2 kidney transplant trial results and substantial capital raises to fund ongoing operations.

Summary

• Eledon Pharmaceuticals reported a net loss of $35.170 million for the nine months ended September 30, 2025, a significant increase from the $8.433 million net income (as restated) for the same period in 2024.
• Research and development expenses increased by $14.7 million to $48.776 million for the nine months ended September 30, 2025, primarily due to increased activities in kidney transplantation trials and manufacturing.
• General and administrative expenses rose by $1.1 million to $12.991 million for the nine months ended September 30, 2025, driven by higher professional services and headcount.
• Cash and cash equivalents, along with short-term investments, totaled $93.4 million as of September 30, 2025, down from $140.178 million at December 31, 2024.
• The Phase 2 BESTOW trial for tegoprubart in kidney transplant rejection prevention did not achieve statistical significance for its primary endpoint (eGFR at 12 months) compared to tacrolimus, though it demonstrated strong renal function and a favorable safety profile.
• Tegoprubart showed significantly lower rates of new-onset diabetes (1 in 47 vs. 1 in 6), tremor (1.6% vs. 25.0%), and cardiovascular effects compared to tacrolimus in the BESTOW trial.
• The efficacy failure composite endpoint (death, graft loss, biopsy proven acute rejection) was 22% for tegoprubart versus 17% for tacrolimus, demonstrating non-inferiority within a 20% margin.
• The company's clinical development program for Amyotrophic Lateral Sclerosis (ALS) is currently unable to continue without additional specific financing.
• Positive data from an investigator-initiated trial for islet cell transplantation (ICT) showed three patients achieved insulin independence and stable islet graft function with tegoprubart, with islet engraftment 2-3 times higher than historical tacrolimus patients.
• The company completed a $53.6 million (estimated net proceeds) underwritten public offering on November 13, 2025, following previous capital raises in 2023 and 2024.
• Financial statements for prior periods (Q3 2024 and Q2 2025) were restated due to incorrect classification of Preferred Stock and earnings per share calculation methodology.
• A material weakness in internal control over financial reporting was identified as of September 30, 2025, which led to the restatements, and remediation efforts are ongoing.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including increased net losses and substantial cash burn, necessitating frequent capital raises that dilute existing shareholders. While there are promising secondary efficacy and safety data from kidney transplant trials and positive early results in islet cell transplantation, the primary endpoint miss in the pivotal BESTOW trial and the halt of the ALS program due to funding issues introduce considerable uncertainty and risk. The identified material weakness in internal controls further adds to concerns.

Positives

• Tegoprubart in Phase 1b kidney transplantation showed mean eGFR above 60 mL/min/1.73m2 at each reported time point after day 30, with an overall mean of 70.5 mL/min/1.73m2, comparing favorably to historical standard of care (approx. 53 mL/min/1.73m2).
• Preliminary abbreviated iBox data for tegoprubart in kidney transplantation suggests improved 5-year graft survival (over 96%) compared to historical calcineurin inhibitors.
• Tegoprubart demonstrated a favorable safety and tolerability profile in the Phase 2 BESTOW trial, with significantly lower rates of new-onset diabetes (1 in 47 vs. 1 in 6 for tacrolimus), tremor (1.6% vs. 25.0%), and cardiovascular effects compared to tacrolimus.
• Delayed graft function occurred less often with tegoprubart (14.3% vs. 25%) and required shorter dialysis (4.6 days vs. 6.1 days) in the BESTOW trial.
• Sepsis or bacteremia occurred less frequently in the tegoprubart arm (4.8% vs. 17.2%) in the BESTOW trial.
• All three patients in the investigator-initiated islet cell transplantation (ICT) trial achieved stable islet graft function, improved blood glucose control, and insulin independence with tegoprubart, with islet engraftment 2-3 times higher than historical tacrolimus patients.
• The company successfully raised approximately $53.6 million in net proceeds from an underwritten public offering that closed on November 13, 2025, providing additional liquidity.

Negatives

• The company reported a net loss of $35.170 million for the nine months ended September 30, 2025, a significant worsening from the $8.433 million net income (as restated) in the prior year period.
• Cash and cash equivalents decreased from $20.549 million at December 31, 2024, to $3.669 million at September 30, 2025, indicating significant cash burn.
• The Phase 2 BESTOW trial for tegoprubart in kidney transplant rejection prevention did not meet its primary endpoint of statistical significance for eGFR at 12 months.
• The rate of acute rejection in all biopsies was higher in the tegoprubart group (20.6%) compared to the tacrolimus group (14.1%) in the BESTOW trial.
• The company is unable to continue clinical development of tegoprubart for Amyotrophic Lateral Sclerosis (ALS) without additional specific financing for that program.
• Financial statements for prior periods (Q3 2024 and Q2 2025) were restated due to a material weakness in internal control over financial reporting related to Preferred Stock classification and EPS calculation.
• A material weakness in internal control over financial reporting was identified as of September 30, 2025, which led to the restatements, and remediation efforts are ongoing.

Risks

• The company's short operating history and shifts in business strategy make it difficult to evaluate success and future viability.
• Significant operating losses have been incurred since inception, and the company expects to continue incurring losses, potentially never achieving profitability.
• Additional funding will be required to complete the development of the lead drug candidate, and inability to raise capital on acceptable terms could force significant alteration of business strategy, curtailment of operations, or liquidation.
• Issuances of common stock, including those from outstanding warrants or convertible securities, could result in significant dilution and cause the stock price to fall.
• Product candidates are in early stages of clinical development and may not be successfully developed, leading to material harm if development or commercialization is delayed or unsuccessful.
• Unfavorable global economic conditions, including inflation and interest rates, could adversely affect the business and ability to obtain financing.
• Adverse conditions in financial markets, including bank failures, could adversely affect liquidity and financial performance.
• Drug development is a lengthy, expensive process with uncertain outcomes, including failure to demonstrate safety and efficacy to regulatory authorities.
• Results of non-clinical studies and early clinical trials may not be predictive of later-stage clinical trials, and additional safety studies may be required.
• Delays or difficulties in patient enrollment in clinical trials could delay or prevent regulatory approvals and increase expenses.
• Identification of serious adverse events or unacceptable side effects during development may require abandonment or limitation of product candidate development.
• Future success depends on the ability to retain executives and key employees and to attract, retain, and motivate qualified personnel.
• Failure to obtain or delays in obtaining required regulatory approvals, or approvals for narrow indications, could materially impair revenue generation.
• Legislation regulating pharmaceutical and healthcare industries may increase the difficulty and cost of obtaining marketing approval and commercializing product candidates, and affect prices.
• Internal computer systems, or those of third parties, may fail or suffer security breaches, disrupting development programs or leading to data loss.
• Compromise of privacy, security, integrity, or confidentiality of sensitive information or failure to comply with data privacy obligations could materially harm the business.
• Even with marketing approval, product candidates may fail to achieve necessary market acceptance by physicians, patients, and third-party payers.
• Later discovery of less effectiveness or undesirable side effects after marketing approval could compromise the ability to market the product.
• Substantial competition exists, potentially leading to others developing or commercializing competing products more successfully.
• Uncertainty regarding insurance coverage and reimbursement status of newly-approved products could limit marketability and revenue generation.
• Reliance on third parties for manufacturing increases the risk of insufficient quantities, unacceptable cost, or quality issues, delaying or impairing development/commercialization.
• Dependence on Contract Research Organizations (CROs) and other third parties for testing and R&D activities means outcomes are partially beyond the company's control.
• Inability to obtain and maintain sufficiently broad intellectual property protection could allow competitors to develop similar products.
• Public health crises, including pandemics or epidemics, could adversely affect the business.
• The company's stock price could be volatile and drop unexpectedly.
• Failure to establish and maintain proper and effective internal control over financial reporting could harm operating results and business operations.
• Provisions in corporate charter and Delaware law could make an acquisition more difficult and prevent stockholder attempts to replace management.

Future Outlook

The company expects to continue incurring significant net losses into the foreseeable future due to ongoing research and development activities. Existing cash, cash equivalents, and marketable securities are projected to fund operations for at least the next 12 months from the filing date. However, additional financing will be required to fund future operations, including the continued clinical development of tegoprubart for ALS, which is currently stalled without specific funding. The company will monitor its liquidity and may pursue further financing if market conditions are favorable or for strategic considerations.

Management Comments

• "We believe these results, if replicated in a Phase 3 study, would be sufficient to support tegoprubart's approvability." (Regarding Phase 2 BESTOW trial results)
• "We are unable to continue our clinical development of tegoprubart for people with ALS without additional financing specific for our ALS program, and we can provide no assurances that we will be able to obtain financing on acceptable terms or at all."

Industry Context

Eledon Pharmaceuticals operates in the highly competitive clinical stage biotechnology sector, focusing on the CD40 Ligand pathway for immunosuppression in organ transplantation and neurodegenerative diseases like ALS. The company aims to address the limitations of current standard-of-care immunosuppressive drugs, such as calcineurin inhibitors (CNIs), which are associated with significant toxic side effects. The positive safety profile of tegoprubart, particularly the absence of CNI-related side effects, positions it as a potential innovation in transplant medicine. However, the ALS program's halt highlights the significant capital requirements and challenges in developing therapies for complex diseases, a common hurdle in the industry. The xenotransplantation collaboration with eGenesis also places Eledon at the forefront of emerging transplant technologies.

Comparison to Industry Standards

• In the Phase 1b kidney transplantation trial, tegoprubart achieved a mean eGFR of 70.5 mL/min/1.73m2 for all reported time points after day 30 post-transplant, which compares favorably to historical studies using standard of care CNI-based immunosuppression that typically report aggregate mean eGFRs of approximately 53 mL/min/1.73m2.
• In the Phase 2 BESTOW trial, tegoprubart achieved an eGFR of approximately 69 mL/min/1.73 m2 at 12 months (n=51) compared to 66 mL/min/1.73 m2 for tacrolimus (n=56), delivering what the company believes is the highest mean eGFR level reported to date in kidney transplant clinical trials evaluating rejection prevention.
• The BESTOW trial showed significantly lower rates of new-onset diabetes (approximately 1 in 47 patients) for tegoprubart compared to tacrolimus (approximately 1 in 6 patients), and markedly lower tremor (1.6% vs. 25.0%), indicating a superior safety profile against common CNI side effects.
• Preliminary abbreviated iBox data from the Phase 1b study showed scores of -3.75 (intention-to-treat) and -4.11 (on-treatment) for tegoprubart, which compare favorably to a -2.98 historical mean for calcineurin inhibitors, suggesting a predicted 5-year allograft survival rate of over 96% for tegoprubart.
• In the investigator-initiated islet cell transplantation trial, islet engraftment in patients treated with tegoprubart was two to three times higher than that observed in comparable historical patients treated with tacrolimus, suggesting reduced toxicity to transplanted islet cells.

Corporate Governance

Stakeholder Impact

• Shareholders: Experience significant dilution from recent and ongoing capital raises, face increased risk due to substantial net losses and cash burn, and potential stock price volatility. The material weakness in internal controls also poses a risk to financial reporting reliability.
• Kidney Transplant Patients: May benefit from tegoprubart's potential to offer improved graft function and a more favorable safety profile compared to current standard-of-care immunosuppression, reducing side effects like new-onset diabetes and tremor.
• ALS Patients: The halt of the ALS clinical development program due to lack of specific financing means a delay or cessation of a potential new treatment option for this severe condition.
• Islet Cell Transplant Patients: Early positive data from an investigator-initiated trial suggests tegoprubart could lead to insulin independence and better graft function, offering a promising new approach for Type 1 Diabetes.
• Employees: Higher headcount in R&D and G&A functions indicates growth in personnel, but the company's financial challenges and need for continuous funding could create job insecurity if capital is not secured.

Next Steps

• Continue to monitor and evaluate the effectiveness of internal control over financial reporting to remediate the identified material weakness.
• Seek additional financing to fund future operations, including the potential continuation of the ALS clinical development program.
• Enroll an additional six patients in the investigator-initiated islet cell transplantation study by the end of 2025.
• Potentially pursue a Phase 3 study for tegoprubart in kidney transplantation, based on the non-inferiority and favorable safety profile observed in the BESTOW trial.

Key Dates

Recommendation

Eledon Pharmaceuticals presents a mixed investment profile. While the Phase 2 BESTOW trial for kidney transplantation missed its primary endpoint, the strong secondary data, particularly the superior safety profile compared to tacrolimus (e.g., significantly lower rates of new-onset diabetes and tremor), and promising early results in islet cell transplantation, suggest potential long-term value for tegoprubart. However, the company's financial position is challenging, marked by significant net losses, substantial cash burn, and a reliance on frequent capital raises, which cause considerable shareholder dilution. The halt of the ALS program due to funding constraints and the identified material weakness in internal controls add to the risk. Given the blend of promising clinical potential and significant financial and operational hurdles, a 'hold' recommendation is appropriate. Investors should await further clarity on Phase 3 development plans, resolution of the internal control weakness, and a more sustainable financial trajectory before considering further investment.

Keywords

Eledon Pharmaceuticals, Tegoprubart, Kidney Transplantation, Immunosuppression, CD40 Ligand, ALS, Islet Cell Transplantation, Biotechnology, Clinical Trials, SEC Filing, 10-Q, Financial Results, Drug Development, Orphan Drug, Capital Raise